Literature DB >> 9116699

Serum and urinary interleukin-6 in systemic lupus erythematosus.

E Peterson1, A D Robertson, W Emlen.   

Abstract

Dysregulation of IL-6 production has been proposed as a pathogenic mechanism in SLE. We asked if serum or urine IL-6 levels could serve as indicators of systemic lupus erythematosus (SLE) disease activity. Using a sensitive enzyme-linked immunosorbent assay (ELISA), we measured serum and urine IL-6 in 56 SLE patients. Disease activity was assessed using a standard clinical index, the Systemic Lupus Activity Measure (SLAM). Only seven of 56 SLE patients had elevated serum IL-6 levels, compared with 1 of 32 controls (NS). SLE disease activity did not correlate with serum IL-6 levels. Sixteen of 50 SLE patients in whom urine IL-6 was measured exhibited elevated urine IL-6 levels, compared with 1 of 17 controls (p = < 0.05). Urine IL-6 levels correlated with overall disease activity and with the presence of active urinary sediment. Our results indicate that serum IL-6 is not a predictor of disease activity in SLE, but that urine IL-6 may be a marker of active nephritis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9116699     DOI: 10.1177/096120339600500603

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  28 in total

1.  Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Authors:  Gabor G Illei; Yuko Shirota; Cheryl H Yarboro; Jimmy Daruwalla; Edward Tackey; Kazuki Takada; Thomas Fleisher; James E Balow; Peter E Lipsky
Journal:  Arthritis Rheum       Date:  2010-02

2.  Dendritic cells from lupus-prone mice are defective in repressing immunoglobulin secretion.

Authors:  Mileka R Gilbert; Diane G Carnathan; Patricia C Cogswell; Li Lin; Albert S Baldwin; Barbara J Vilen
Journal:  J Immunol       Date:  2007-04-15       Impact factor: 5.422

Review 3.  Why targeted therapies are necessary for systemic lupus erythematosus.

Authors:  L Durcan; M Petri
Journal:  Lupus       Date:  2016-09       Impact factor: 2.911

Review 4.  Lupus nephritis: the evolving role of novel therapeutics.

Authors:  Brad H Rovin; Samir V Parikh
Journal:  Am J Kidney Dis       Date:  2014-01-07       Impact factor: 8.860

Review 5.  Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implications.

Authors:  Natasha Jordan; David D'Cruz
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-12       Impact factor: 5.346

6.  Neuraminidase activity mediates IL-6 production by activated lupus-prone mesangial cells.

Authors:  Kamala Sundararaj; Jessalyn I Rodgers; Subathra Marimuthu; Leah J Siskind; Evelyn Bruner; Tamara K Nowling
Journal:  Am J Physiol Renal Physiol       Date:  2017-12-20

7.  Imbalance between interleukin-6 and adrenomedullin mRNA levels in peripheral blood mononuclear cells of patients with lupus nephritis.

Authors:  Y Nishitani; A Kubo; M Iwano; N Minamino; K Hamano; T Fujimoto; T Nishino; H Shiiki; K Yonemasu; K Dohi
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

Review 8.  Biologic treatments for systemic rheumatic diseases.

Authors:  Y Shirota; G G Illei; N P Nikolov
Journal:  Oral Dis       Date:  2008-02-14       Impact factor: 3.511

Review 9.  Rationale for interleukin-6 blockade in systemic lupus erythematosus.

Authors:  E Tackey; P E Lipsky; G G Illei
Journal:  Lupus       Date:  2004       Impact factor: 2.911

10.  Increased activation of toll-like receptors-7 and -8 of peripheral blood mononuclear cells and upregulated serum cytokines in patients with pediatric systemic lupus erythematosus.

Authors:  Yanyan Guo; Qinghe Chai; Yun Zhao; Peng Li; Jie Qiao; Jianping Huang
Journal:  Int J Clin Exp Med       Date:  2015-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.